yahoo Press
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review
Images
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Wave Life Sciences Ltd. is among the best Robinhood stocks to invest in. TheFly reported earlier on March 10 that Canaccord Genuity raised its price target for WVE to $52 from $43 while keeping a Buy rating on the stock. The update followed a review of the company’s pipeline, including WVE-007 for obesity and WVE-006 for AATD, after discussions with management and a refreshed financial model. The recent positive analyst sentiment reflects Wave Life Sciences Ltd. (NASDAQ:WVE)’ operational announcement on March 5, 2026, when the company confirmed that data from its ongoing RestorAATion-2 clinical trial of WVE-006, an investigational GalNAc-conjugated RNA editing therapy for alpha-1 antitrypsin deficiency (AATD), would be presented as a late-breaking oral session at the upcoming American Thoracic Society (ATS) International Conference in Orlando, Florida, May 15–20, 2026. The presentation will include results from both the 400 mg multidose cohort and the 600 mg single-dose cohort. WVE emphasized that RNA editing directly addresses the underlying single-gene cause of AATD, impacting both lung and liver manifestations, while regulatory discussions toward potential accelerated approval for WVE-006 are ongoing, with feedback anticipated in mid-2026. The company also remains on track to release INLIGHT trial data for WVE-007 targeting obesity later this month. Wave Life Sciences Ltd. (NASDAQ:WVE) is a biotechnology company focused on developing proprietary stereopure oligonucleotide therapies to treat genetic diseases, combining precision chemistry with targeted drug design to address serious unmet medical needs. While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years Disclosure: None. Follow Insider Monkey on Google News.